@article {Michelsene001280, author = {Brigitte Michelsen and Ulf Lindstr{\"o}m and Catalin Codreanu and Adrian Ciurea and Jakub Zavada and Anne Gitte Loft and Manuel Pombo-Suarez and Fatos Onen and Tore K Kvien and Ziga Rotar and Maria Jose Santos and Florenzo Iannone and Anna-Mari Hokkanen and Bjorn Gudbjornsson and Johan Askling and Ruxandra Ionescu and Michael J Nissen and Karel Pavelka and Carlos Sanchez-Piedra and Servet Akar and Joseph Sexton and Matija Tomsic and Helena Santos and Marco Sebastiani and Jenny {\"O}sterlund and Arni Jon Geirsson and Gary Macfarlane and Irene van der Horst-Bruinsma and Stylianos Georgiadis and Cecilie Heegaard Brahe and Lykke Midtb{\o}ll {\O}rnbjerg and Merete Lund Hetland and Mikkel {\O}stergaard}, title = {Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration}, volume = {6}, number = {3}, elocation-id = {e001280}, year = {2020}, doi = {10.1136/rmdopen-2020-001280}, publisher = {BMJ Specialist Journals}, abstract = {Objectives To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.Methods Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ{\texttwosuperior} and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \<2/\<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) \<1.3/\<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)).Results We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82\%/72\%, with significant (p\<0.001) differences between the registries (6-month: 70{\textendash}93\%, 12-month: 53{\textendash}86\%) and across number of previous b/tsDMARDs (b/tsDMARD-na{\"\i}ve: 90\%/84\%, 1 prior b/tsDMARD: 83\%/73\%, >=2 prior b/tsDMARDs: 78\%/66\%). Overall 6-month/12-month BASDAI\<4 were observed in 51\%/51\%, ASDAS\<1.3 in 9\%/11\%, BASDAI50 in 53\%/47\%, ASAS40 in 28\%/22\%, ASDAS-CII in 49\%/46\% and ASDAS-MI in 25\%/26\% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-na{\"\i}ve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness.Conclusions In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12~months of treatment were high. Secukinumab effectiveness was consistently better for biona{\"\i}ve patients, independent of time since diagnosis and differed across the European countries.}, URL = {https://rmdopen.bmj.com/content/6/3/e001280}, eprint = {https://rmdopen.bmj.com/content/6/3/e001280.full.pdf}, journal = {RMD Open} }